Proteasome Inhibitor Drugs

• Published in: Annual review of pharmacology and toxicology Vol. 60; no. 1; pp. 457 - 476
• Main Author: Fricker, Lloyd D
• Format: Journal Article
• Language: English
• Published: United States Annual Reviews 06-01-2020
• Subjects: bortezomib; carfilzomib; ixazomib; peptide; protease; ubiquitin; protease; peptide; bortezomib; ubiquitin; carfilzomib; ixazomib
• ISSN: 0362-1642; 1545-4304
• DOI: 10.1146/annurev-pharmtox-010919-023603

Proteasomes are large, multicatalytic protein complexes that cleave cellular proteins into peptides. There are many distinct forms of proteasomes that differ in catalytically active subunits, regulatory subunits, and associated proteins. Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and mantle cell lymphoma, and they are being investigated for other diseases. Bortezomib (Velcade) was the first proteasome inhibitor to be approved by the US Food and Drug Administration. Carfilzomib (Kyprolis) and ixazomib (Ninlaro) have recently been approved, and more drugs are in development. While the primary mechanism of action is inhibition of the proteasome, the downstream events that lead to selective cell death are not entirely clear. Proteasome inhibitors have been found to affect protein turnover but at concentrations that are much higher than those achieved clinically, raising the possibility that some of the effects of proteasome inhibitors are mediated by other mechanisms.